Lonza Forms JV With Shanghai Fosun To Tap Chinese Generics Market
This article was originally published in PharmAsia News
Executive Summary
Swiss firm Lonza Group AG, a global supplier of active pharmaceutical ingredients has announced a joint venture with Shanghai Fosun Pharmaceutical. The 50/50 JV will develop and launch a portfolio of generic products in China